A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma - SPARCC
Stephanie Berg
25 participants
Nov 24, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC). The name of the study drugs involved in this research study is: * Sasanlimab (a type of monoclonal antibody) * Palbociclib (a type of kinase inhibitor) * Axitinib (a type of Vascular endothelial growth factor inhibitor)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Recombinant humanized monoclonal antibody, prefilled syringe, subcutaneous (under the skin) injection per protocol
Cyclin-dependent kinase (CDK) 4/6 inhibitor, tablet taken orally per protocol
Vascular endothelial growth factor (VEGF) inhibitor, tablet taken orally per standard of care
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07123090